IDR 400.0
(-0.5%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 5.19 Billion IDR | -89.17% |
2022 | 48 Billion IDR | -57.2% |
2021 | 112.15 Billion IDR | 85.31% |
2020 | 60.52 Billion IDR | 82.27% |
2019 | 33.2 Billion IDR | 2.93% |
2018 | 32.26 Billion IDR | 34.55% |
2017 | 23.97 Billion IDR | 3292.63% |
2016 | 706.7 Million IDR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q3 | 11.23 Billion IDR | 148.22% |
2024 Q1 | 4.31 Billion IDR | 142.79% |
2024 Q2 | 4.52 Billion IDR | 4.9% |
2023 Q2 | 6.13 Billion IDR | -5.28% |
2023 FY | 5.19 Billion IDR | -89.17% |
2023 Q3 | 2.66 Billion IDR | -56.6% |
2023 Q4 | -10.08 Billion IDR | -478.53% |
2023 Q1 | 6.48 Billion IDR | -13.75% |
2022 FY | 48 Billion IDR | -57.2% |
2022 Q4 | 7.51 Billion IDR | 59.64% |
2022 Q3 | 4.7 Billion IDR | -67.42% |
2022 Q2 | 14.44 Billion IDR | -32.28% |
2022 Q1 | 21.33 Billion IDR | -21.66% |
2021 Q1 | 20.91 Billion IDR | -16.53% |
2021 FY | 112.15 Billion IDR | 85.31% |
2021 Q4 | 27.23 Billion IDR | -20.32% |
2021 Q3 | 34.17 Billion IDR | 14.57% |
2021 Q2 | 29.83 Billion IDR | 42.65% |
2020 Q2 | 7.47 Billion IDR | 237.46% |
2020 Q1 | 2.21 Billion IDR | -91.81% |
2020 FY | 60.52 Billion IDR | 82.27% |
2020 Q4 | 25.05 Billion IDR | -2.8% |
2020 Q3 | 25.77 Billion IDR | 244.81% |
2019 Q2 | 2.5 Billion IDR | 11.04% |
2019 FY | 33.2 Billion IDR | 2.93% |
2019 Q1 | 2.25 Billion IDR | 0.0% |
2019 Q3 | 1.4 Billion IDR | -43.91% |
2019 Q4 | 27.03 Billion IDR | 1824.61% |
2018 Q1 | 4.3 Billion IDR | 0.0% |
2018 FY | 32.26 Billion IDR | 34.55% |
2017 FY | 23.97 Billion IDR | 3292.63% |
2016 FY | 706.7 Million IDR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
PT Enseval Putera Megatrading Tbk. | 688.49 Billion IDR | 99.245% |
PT Kimia Farma (Persero) Tbk | -1485.56 Billion IDR | 100.35% |
PT Millennium Pharmacon International Tbk | 33.08 Billion IDR | 84.289% |
PT Soho Global Health Tbk | 371.34 Billion IDR | 98.6% |